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Abstract
This review examines the most important aspects of the use of topical corticosteroids in oral pathology. We 
provide a detailed analysis of the most common types of corticosteroids used, their methods of application and 
the clinical data that must be managed in order to monitor the effectiveness of the treatment. We also analyze 
the correctable causes of treatment failure and the possible adverse effects that may occur after applying these 
drugs. All of this is achieved by conducting a critical review of these concepts.
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Introduction
Topical corticosteroids (TC) are some of the most com-
mon drugs used in oral pathology for treating atrophic-
erosive lesions that affect the mucosa. This type of le-
sion is rather significant given that it often bleeds and is 
painful; sometimes it is chronic or has a high tendency 
to reappear and to interfere with very important activi-
ties such as eating, drinking, speaking or associating 
with other people, making this type of lesion very de-
bilitating for the patient.  The seriousness of these le-
sions increases in such cases where the gums are af-
fected, given that the bleeding, the inability to brush 
the teeth properly, bad breath and  deterioration of the 
physical appearance of the patient may contribute to 
his or her social isolation. Severe erosive lesions of the 
oral mucosa have classically been treated with systemic 
corticosteroids, although the adverse effects associated 
with the use of these drugs have conditioned the fre-
quent prescription of topical corticosteroids for treating 
these pathologies. However, there are few studies on the 
subject. 
This review includes the most important aspects per-
taining to the use of TCs in oral pathology, particularly 
the application instructions, the most common types of 
TCs, their formulation and the treatment procedures, as 
well as the possible adverse effects associated with their 
use. 
Instructions for using TCs in oral medicine
The use of a TC for treating various pathologies of the 
oral mucosa that may respond to these drugs must ad-
here to one of the following criteria (1, 2): 
- Use of a short course of TCs (2-6 days). This will be 
especially indicated in oral mucosal diseases that have a 
natural tendency towards spontaneous resolution, such 
as non-complex recurrent aphthous stomatitis (RAS), or 
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drug-induced ulcers, once we have removed or replaced 
the causative drug.  The use of this regimen enables re-
ducing the natural duration of the process as well as its 
symptomatology.
- Use of a prolonged course of TCs of an unpredictable 
duration. Diseases eligible for receiving this type of 
treatment are chronic or very recurrent erosive lesions, 
such as some cases of oral lichen planus (OLP), mu-
cous membrane pemphigoid (MMP), or some forms of 
complex recurrent aphthous stomatitis where outbreaks 
occur seamlessly, thereby making it possible for the pa-
tient to suffer permanent lesions, or to be free of lesions 
only for short periods of time. In order to thus reduce 
the percentage of recurrent cases, patients must be in-
formed about the possibility of having to be subjected to 
prolonged treatments, and also about the inadvisability 
of discontinuing the treatment without the express con-
sent of the doctor.
- Use of TCs along with a short course (5-6 days) of sys-
temic corticosteroids. This regimen applies fundamen-
tally to the treatment of very severe erosive lesions in 
which the use of a systemic corticoid will enable a quick 
resolution of the symptoms, in order to then continue 
monitoring the process using a topical corticosteroid.
- Finally, some diseases are not susceptible to be treated 
with TCs. In general, the involvement of multiple muco-
sas and the presence of elevated titers of circulating le-
sion antibodies discourage the use of topical treatments, 
given that the existence of multiple targets and lesion 
antibodies present in the plasma lesion indicate a gener-
alized disorder of the body which will require a system-
ic treatment. Examples of these diseases are pemphigus 
vulgaris and certain forms of MMP with involvement of 
multiple mucous membranes.
The basic rule for managing TCs in oral pathology 
should be to use a TC of a strength that adapts to the 
seriousness of the clinical symptoms, prescribed at the 
lowest concentration possible, (respecting the effective-
ness of the treatment) and in a form that minimizes as 
much as possible the mucosa area exposed to the drug. 
It should be kept in mind that treatment with TCs is 
symptomatic (non-curative). Thus, the suppression of 
the drug or discontinuing the treatment by the patient is 
often followed by a recurrence of the symptoms of the 
disease.  Patients should be clearly informed about this 
aspect (1-3).
TCs commonly used in oral pathology
Although there are different types of TCs with different 
strengths, the clinician should be familiar with a limited 
number of TCs. In the scientific literature on the topic, 
the corticosteroids that have received greater attention 
and on which there is more experience are clobetasol 
propionate (CP), fluocinonide and triamcinolone ac-
etonide.
Clobetasol propionate (CP) is considered to be a super-
potent corticosteroid, and according to some authors, its 
use has enabled restricting the use of systemic corticos-
teroids in oral pathology, given that many of the severe 
erosive lesions that required systemic administration of 
drugs for control of such lesions can now be controlled 
with CP (4). The articles published on the topic recom-
mend using the drug at a concentration that ranges be-
tween 0.025% and 0.05%, two to three times per day, 
and for a period of three to five minutes each applica-
tion. By following this regimen, the CP achieves rapid 
control of the lesions with a low number of applications 
each day, also enabling longer periods free of lesions 
once the treatment is discontinued (5,6). Our group has 
reported excellent results with the use of CP, both in an 
aqueous solution as well as in adhesive forms (4, 7). In 
our opinion, this drug should be reserved for the treat-
ment of severe atrophic-erosive lesions of the oral mu-
cosa, considering those to include multiple or extensive 
lesions that cause intense pain, impeding or making it 
difficult to swallow or speak (1,2) (Fig. 1).
Fig. 1. A) Patient with MMP, presenting severe erosive lesions in 
the cheek mucosa. Lesions are also present in other parts of the oral 
cavity. B) Complete disappearance of the lesions after using 0.05% 
CP in aqueous solution. 
Fluocinonide is considered to be a moderate-high po-
tency corticosteroid. Studies on the subject recommend 
the use of the drug at concentrations ranging between 
0.025% and 0.05%, it being necessary to apply the med-
ication 5-10 times per day and for 3-5 minutes in order 
to obtain results (6). It is a milder TC than clobetasol 
propionate and is less effective in reducing the pain that 
results from the lesions. When using the medication at 
a 0.025% concentration, a complete resolution of the le-
sions is only achieved in 25% of the patients with OLP 
(5,6).
Finally, triamcinolone acetonide is one of the most com-
monly used TCs in oral pathology. It is considered to 
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Fig. 2. A) Patient presenting oral lichenoid lesion (OLL) This small 
atrophic and slightly erosive lesion only appeared in the right cheek 
mucosa. Its low degree of seriousness and its accessible location 
prompted the use of 0.4% triamcinolone acetonide ointment in ora-
base. B) Complete disappearance of the lesion after treatment.
be an average strength TC. Studies on the subject rec-
ommend concentrations that range between 0.05% and 
0.5%, it being necessary to apply the medicine 3-10 
times per day, and for a period of 3 to 5 minutes each 
time in order to achieve results. Some important authors 
in this field do not consider the drug to be very useful, 
presenting as the main drawback the fact that several 
applications are required each day, which poses a sig-
nificant inconvenience for the patient, making it diffi-
cult to comply with the treatment (3,8). However, stud-
ies published with the use of triamcinolone acetonide 
have recently yielded contradictory results, having re-
ported positive effects in the treatment of OLP (9). In 
our opinion, triamcinolone acetonide should be used for 
the treatment of mild erosive lesions, considering such 
lesions to include those that occur with few symptoms 
and which are small in size (1,2) (Fig. 2).
Other less explored TCs are fluticasone propionate, be-
tamethasone sodium phosphate or momethasone.  One 
group has reported very positive results with the use of 
momethasone, and minimal adverse effects (10,11).
Factors that affect the effectiveness of treatment 
with TCs in oral pathology
The intrinsic strength of the drug, which is conditioned 
by the halogenation of its main ingredient (cortisol), 
is one of the factors that influence the effectiveness of 
treatment with TCs. Obviously, the use of a stronger TC 
(CP) implies a greater likelihood of achieving a com-
plete disappearance of the lesions.
The esterification of the cortisol, which increases the 
penetration of the TC through the mucous membranes, 
also increases the effectiveness of the treatment.
The increase of the concentration of the drug, up to a 
certain point, is a factor which increases the possibil-
ity of achieving adequate results. However, it has been 
verified that there is a certain level after which increas-
ing the concentration does not lead to an increase in the 
effectiveness of the TC.
One of the factors that play the largest role in deter-
mining the success of the treatment with a TC is the 
amount of time that the drug comes into direct contact 
with the lesion. This is not surprising, given that the 
basic requirement in a topical treatment is that the drug 
comes into contact with the lesions for the amount of 
time prescribed by the doctor. The amount of time that 
the drug comes into contact with the lesion depends 
fundamentally on the means used for applying the TC. 
The means most often used in oral pathology are adhe-
sive ointments and aqueous solutions. Among adhesive 
ointments, the orabase ointment is one of the most com-
monly used. It is a commercial formula that does not 
contain analgesics or antibiotics. Gels are rarely used 
due to the possibility of causing pain after being ap-
plied. The ointments do not have adhesive properties, 
although they are frequently used as a usual base of the 
main ingredient and as a means for locating it in other 
forms. Finally, it was recently reported that adhesive 
pastes for dentures have very good adherent qualities 
and can be used successfully for applying TC (1,2).
When TC is used in an adhesive form, it is recommend-
ed that a small amount be applied in the target area, 
to not eat or drink for 20 minutes and to not rub the 
medicine against the lesion, so as to avoid irritating the 
area. Some authors recommend supplying the medicine 
to the patient in small containers with the amount nec-
essary for each application. At the end of the treatment, 
the patient should return the empty and full contain-
ers to the doctor, which in turn enables monitoring the 
patient s´ compliance with the treatment (8). 
The main inconvenience raised by the use of TC in 
adhesive form is that it is difficult to perfectly control 
the amount of time that the medicine comes into con-
tact with the lesion, given that according to some stud-
ies, the majority of the medicine quickly spreads away 
from the location where it was initially applied (85-90% 
loss). In addition, it is difficult to apply the medicine on 
deep lesions or to ensure that large lesions come into 
equal contact with the TC.  On the other hand, some 
patients report intolerance to the granular texture of the 
medicine. In our opinion, a TC should be supplied in an 
adhesive form when treating small, isolated lesions, or 
when there are very few lesions and they are easily ac-
cessible, or when the lesions are located on the gums or 
the palate onto which the medicine may be applied us-
ing a customized tray, thereby allowing perfect control 
of the amount of time that the medicine must come into 
contact with the lesion. Patients who wear a full set of 
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dentures can use the dentures as a tray for applying the 
medicine (1,2).
TCs can also be applied in aqueous solutions. The den-
tist must advise the patient of the advantage of not using 
hydroalcoholic solutions that would irremediably cause 
intense pain upon contact with atrophic-erosive lesions, 
and would make it difficult to comply with the treat-
ment. The basic advantages of using aqueous solutions 
are the ability to have perfect control of the time that 
the medicine comes into contact with the lesion, contact 
of the medicine with all of the oral lesions regardless of 
their depth or how large, and it is easier to administer 
the corticosteroid when in the form of an aqueous solu-
tion as opposed to an adhesive form. The main draw-
backs of the aqueous solution are that all of the mucosa, 
whether diseased or healthy, comes into contact with 
the medicine, thereby increasing systemic absorption of 
the medicine and the possibility of involuntary inges-
tion. We believe that the aqueous solutions should be 
used for treating large and deep lesions (1,2).
Objectives of treatment with TCs in oral patho-
logy
Given that treatment with TCs only achieves a symp-
tomatic and not a curative effect, the fundamental ob-
jective of the treatment with TC in oral pathology is to 
ensure that the symptoms of the illness disappear, re-
storing the patient s´ ability to ingest food, speak, carry 
out proper oral hygiene and a normal relationship with 
the people of his or her environment. In essence, the 
main objective of the treatment is to suppress or reduce 
the pain. This is also usually accompanied by a disap-
pearance or a considerable reduction of the size of the 
ulcerations. Changing the appearance of the white le-
sions in OLP or ensuring that the atrophy disappears 
are not the objectives of the treatment. The white lesions 
that accompany OLP have an unpredictable response to 
corticosteroids, and in some cases, the white color even 
increases in intensity.  Similarly, the area that responds 
worse to treatment with TCs is usually the mucosal at-
rophy, which manifests as a fragile and delicate mucosa 
with a reddened appearance (4,7).  Usually, after apply-
ing TC and even after having completely resolved the 
pain, there are areas in the oral cavity which still pres-
ent characteristics of atrophic mucosa. These atrophic 
lesions are usually not painful and, in our experience, it 
is very difficult to full restore the normal appearance of 
the oral mucosa.   We have reported that the conversion 
of a painful erosive lesion into a non-painful atrophic 
lesion should be considered a success in the treatment 
with TCs. The non-objective parameters of the treat-
ment should be taken into consideration in order to 
avoid unnecessary overdoses of the drug or confusion 
regarding the effectiveness of the treatment (1,2).
Treatment failures
Despite the fact that correct instructions and use of TCs 
in oral pathology reveal a high degree of success in the 
treatment, a small percentage of patients do not respond 
adequately to these drugs. In our study (4), 6% of the 
patients with severe erosive lesions of the oral mucosa 
did not respond to treatment with CP. Before attributing 
the treatment failure to an actual lack of response to 
the TC, some of the possible causes of false treatment 
failures should be analyzed:
- The incorrect diagnosis and thus the incorrect indica-
tion of a TC is a cause of false treatment failure.
- Prescription of a TC of an inadequate strength, in an 
inadequate form or for a reduced amount of time is a 
common cause of false treatment failure.   In our opin-
ion, this is especially frequent with the use of triamci-
nolone acetonide in adhesive forms when prescribed by 
inexperienced dentists for the treatment of severe ero-
sive lesions of the oral mucosa.
- Poor cooperation on the part of the patient is a cause of 
false lack of response to the treatment.
- Finally, some adverse affects or abnormal reactions of 
the mucosa following the treatment may also be con-
fused with a lack of response. The appearance of ery-
thematous candidiasis, with reddening and pain, as an 
adverse effect of the TC can be interpreted as a worsen-
ing of the symptoms of the illness. It may also occur 
with the increase of white lesions in patients with OLP 
or with the persistence of non-painful atrophic lesions 
following the use of TCs (1,2).
Adverse effects of treatment with TCs in oral 
pathology
- Local adverse effects
Among the local adverse effects of treatment with TCs, 
there is the appearance of oral candidiasis in 25% - 55% 
of the patients. The frequency of presenting candidiasis 
as a complication of the treatment is directly related 
with the use of stronger TCs in aqueous forms, for pro-
longed periods of times, and at high concentrations. The 
status of a healthy carrier (healthy patients who develop 
more than 50 colony-forming units in an oral mucosa 
culture) also affects the frequency of occurrence. Oral 
candidiasis secondary to the use of TCs is easily treated 
with nystatin antifungal cream. However, applying nys-
tatin formula 100 000 UI/cc is very effective in prevent-
ing this complication. In our opinion, one should always 
proceed in this manner when anticipating a treatment for 
more than 10 days, especially when using high strength 
topical corticosteroids in aqueous solutions (3,8). 
Other local adverse effects are burning mouth, hypo-
geusia, oral hairy leukoplakia and hypersensitive reac-
tions to the drug (3,12).
- Systemic adverse effects
In patients treated with high-potency TCs, there may 
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be adverse effects that show the systemic absorption of 
the drug with inhibition of the hypothalamic-pituitary-
adrenal axis and secondary adrenal insufficiency. In 
our studies, these have been moon face, hirsutism and 
capillary fragility (4).  Such effects have always mani-
fested in a small number of patients. Through the de-
termination of basal plasma cortisol in patients treated 
with CP in aqueous solution, we have verified (data not 
published) the existence of an inhibition of the hypo-
thalamic-pituitary-adrenal axis in 85% of the cases, 
occurring in the initial phases of treatment when maxi-
mum dosages are used (3 rinses/day). This indicates that 
a secondary adrenal insufficiency is occurring due to 
an exogenous glucocorticosteroid exposure, which is 
very often asymptomatic. However, in the maintenance 
phases, when using very low dosages of the drug in or-
der to maintain the effect of the treatment (one rinse 
every other day), only 4% of patients present low levels 
of plasma cortisol, indicative of inhibition of the axis 
with adrenal insufficiency.  This indicates that usually 
the secondary adrenal insufficiency to the treatment 
with high dosages of CP is reversible when the dos-
age is reduced; and on the other hand, this reveals that 
maintenance treatment with low dosages of CP is very 
safe. However, although there is not an consensus on the 
subject, it should be taken into consideration that these 
patients may be at risk for developing an acute adrenal 
crisis (Addisonian crisis) in the event that, due to stress-
ful circumstances (major surgery, severe traumatism, 
acute infection, etc.), an increased physiological adren-
aline production of corstisol -incapable of reaching the 
inhibited axis- should be required.  This situation may 
require the exogenous supply of cortisol. We believe 
this situation to have two implications that are of inter-
est.  Patients undergoing treatment of a high strength 
TC should be subject to evaluations on the evolution of 
their hypothalamic-pituitary-adrenal axis by means of 
determining the basal plasma cortisol (levels less than 
3μg/dl are indicative of inhibition) at least once during 
the onset of the treatment and during the maintenance 
period. In case of inhibition of the axis, patients and 
their relatives should be informed of these aspects, and 
should perhaps carry a letter for the doctor who would 
have to treat them in the hypothetical case that medical 
attention should be required for a serious illness. Gener-
ally speaking, the usual dental procedures (extraction, 
curettage, gingivectomy, etc.) do not appear to require 
an exogenous supply of glucocorticosteroids in patients 
with inhibition of the hypothalamic-pituitary-adrenal 
axis (13-15).  
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